CD2 and neoplasm: In vitro studies demonstrated that T/NK-mediated cytotoxicity could be restored by re-expression of wild-type CD58 [20], suggesting the deficiency of CD58 restrains the recognition of tumor cells by T/NK cells and evades immune surveillance in a CD2/CD58-dependent manner.